In June/July 2019, Scandion Oncology A/S (“Scandion Oncology”) conducted a rights issue of units in which the general public was given the opportunity to subscribe. Through the rights issue, a total of 7,144,590 shares and 2,381,530 warrants of series TO 1 were issued. The rights issue of units has now been fully registered at the Danish Business Authority. Last day of trading in BTU (paid-up for units) will be on July 30, 2019 and the stop date will be on August 1, 2019.
A total of 7,144,590 shares and 2,381,530 warrants of series TO 1 have been registered at the Danish Business Authority. These are estimated to be distributed to each VP account/depot on August 5, 2019. After registration, the number of shares in Scandion Oncology amount to 19,052,241 shares and the share capital amounts to DKK 1,400,339.7135.
Financial adviser, issuing agent and legal adviser
Sedermera Fondkommission is the financial advisor and issuing agent to Scandion Oncology in connection with the rights issue. Markets & Corporate Law acts as the legal advisor.
For more information regarding Scandion, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, was found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. In addition, SCO-101 restores chemotherapy sensitivity in in vitro grown resistant cancer cells. Scandion Oncology will in Q4 2019 initiate a clinical phase II study with SCO-101 in combination with chemotherapy. Scandion Oncology was listed on Spotlight, Sweden in November 2018.